Guided Therapeutics (GTHP) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 10, 2024
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		56,550,370
Entity File Number	000-22179
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite B
Entity Address City Or Town	Peachtree Corners
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Local Phone Number	242-8723
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 275	$ 591
Accounts receivable, net of allowance for credit losses of $2 at March 31, 2024 and December 31, 2023	2	7
Inventory, net of reserves of $818 at March 31, 2024 and December 31, 2023	632	632
Other current assets	112	163
Total current assets	1,021	1,393
Non-Current Assets:
Property and equipment, net	28	32
Operating lease right-of-use assets, net of amortization	185	227
Other assets	17	17
Total non-current assets	230	276
TOTAL ASSETS	1,251	1,669
Current Liabilities:
Accounts payable	2,143	1,991
Accounts payable, related parties	34	32
Accrued liabilities	840	1,068
Deferred revenue	748	424
Current portion of lease liability	99	91
Current portion of long-term debt, related parties	520	39
Short-term notes payable	112	59
Short-term convertible debt	94	1,105
Short-term convertible debt in default	1,130	0
Derivative liability at fair value	12	0
Total current liabilities	5,732	4,809
Long-Term Liabilities
Long-term lease liability	104	155
Long-term notes payable	59	0
Long-term debt, related parties	23	511
Total long-term liabilities	186	666
Total liabilities	5,918	5,475
STOCKHOLDERS' DEFICIT:
Common stock, $.001 par value; 500,000 shares authorized, 55,614 and 54,105 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	3,442	3,441
Additional paid-in capital	141,320	140,983
Treasury stock at cost	(132)	(132)
Accumulated deficit	(152,317)	(151,118)
Total stockholders' deficit	(4,667)	(3,806)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,251	1,669
Series C Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	105	105
Series C1 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	170	170
Series C2 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	439	439
Series F-2 Convertible Preferred Shares [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, value	475	475
Series D Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	159	159
Series E Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	834	834
Series F Convertible Preferred Shares
STOCKHOLDERS' DEFICIT:
Preferred stock, value	$ 838	$ 838

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable, net of allowance	$ 2,000	$ 2,000
Inventory, net of reserves	$ 818,000	$ 818,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	56,267,000	54,105,000
Common stock, outstanding	54,105,000	54,105,000
Series C Convertible Preferred Shares [Member]
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	9,000	9,000
Preferred stock, liquidation preference	$ 286,000	$ 286,000
Preferred stock, issued	300	300
Preferred stock, outstanding	300	300
Series F-2 Convertible Preferred Shares [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, liquidation preference	$ 520,000	$ 520,000
Preferred stock, issued	500	500
Preferred stock, outstanding	500	500
Series D Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	6,000	6,000
Preferred stock, liquidation preference	$ 438,000	$ 438,000
Preferred stock, issued	400	400
Preferred stock, outstanding	400	400
Series E Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, liquidation preference	$ 883,000	$ 883,000
Preferred stock, issued	900	900
Preferred stock, outstanding	900	900
Series F Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	1,500	1,500
Preferred stock, liquidation preference	$ 1,006,000	$ 1,006,000
Preferred stock, issued	1,100	1,100
Preferred stock, outstanding	1,100	1,100
Series C-1 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	20,300	20,300
Preferred stock, liquidation preference	$ 1,049,000	$ 1,049,000
Preferred stock, issued	1,000	1,000
Preferred stock, outstanding	1,000	1,000
Series C-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, liquidation preference	$ 2,700,000	$ 2,700,000
Preferred stock, issued	2,700	2,700
Preferred stock, outstanding	2,700	2,700

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Sales - devices and disposables	$ 0	$ 44	$ 6	$ 66
Cost of goods sold	0	33	2	42
Gross profit	0	11	4	24
Operating expenses:
Research and development	222	66	275	73
Sales and marketing	69	61	142	134
General and administrative	364	1,389	600	2,166
Total operating expenses	655	1,516	1,017	2,373
Loss from operations	(655)	(1,505)	(1,013)	(2,349)
Other income (expenses):
Interest expense	(75)	(69)	(139)	(134)
Interest income	0	0	3	0
Change in fair value of derivative liability	(7)	0	(7)	5
Gain from extinguishment of debt	16	17	33	52
Other income (expenses)	12	0	12	0
Total other income (expense)	(54)	(52)	(98)	(77)
Loss before income taxes	(709)	(1,557)	(1,111)	(2,426)
Provision for income taxes	0	0	0	0
Net loss	(709)	(1,557)	(1,111)	(2,426)
Deemed dividend for warrant exchanges	0	0	0	(65)
Preferred stock dividends	(49)	(47)	(88)	(82)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (758)	$ (1,604)	$ (1,199)	$ (2,573)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
Diluted	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
Weighted average shares outstanding
Weighted average shares outstanding Basic	55,986	50,970	55,368	50,138
Weighted average shares outstanding Diluted	55,986	50,970	55,368	50,138

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F2 [Member]	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock
Balance, shares at Dec. 31, 2022		0	1	2	1	1	1	3	48,596
Balance, amount at Dec. 31, 2022	$ (2,883)	$ 105	$ 170	$ 439	$ 159	$ 839	$ 880	$ 489	$ 3,437	$ 138,090	$ (147,359)	$ (132)
Common stock warrants exercised, shares									1,120
Common stock warrants exercised amount	231	0	0	0	0	0	0	0	$ 1	230	0	0
Issuance of common stock for payment of Series D preferred dividends shares									59
Issuance of common stock for payment of Series D preferred dividends amount	14	0	0	0	0	0	0	0	$ 0	14	0	0
Issuance of common stock for payment of Series E preferred dividends shares									26
Issuance of common stock for payment of Series E preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F preferred dividends shares									233
Issuance of common stock for payment of Series F preferred dividends amount	53	0	0	0	0	0	0	0	$ 0	53	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									121
Issuance of common stock for payment of Series F-2 preferred dividends amount	29	0	0	0	0	0	0	0	$ 0	29	0	0
Conversion of Series E preferred stock to common stock shares									20
Conversion of Series E preferred stock to common stock amount	0	0	0	0	0	(5)	0	0	$ 0	5	0	0
Conversion of Series F preferred stock to common stock shares									200
Conversion of Series F preferred stock to common stock amount	0	0	0	0	0	0	(42)	0	$ 0	42	0	0
Conversion of Series F-2 preferred stock to common stock shares									60
Conversion of Series F-2 preferred stock to common stock amount	0	0	0	0	0	0	0	(14)	$ 0	14	0	0
Issuance of common stock for payment of interest shares									178
Issuance of common stock for payment of interest amount	59	0	0	0	0	0	0	0	$ 0	59	0	0
Stock-based compensation shares									400
Stock-based compensation amount	1,683	0	0	0	0	0	0	0	$ 0	1,683	0	0
Impact of warrant exchanges amount	0	0	0	0	0	0	0	0	0	65	(65)	0
Accrued preferred dividends amount	(83)	0	0	0	0	0	0	0	0	(1)	(82)	0
Net Income (Loss)	(2,426)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	0	(2,426)	0
Stock-based compensation	1,683
Balance, shares at Jun. 30, 2023		0	1	2	1	1	1	3	51,011
Balance, amount at Jun. 30, 2023	(3,315)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,438	140,291	(149,932)	(132)
Balance, shares at Mar. 31, 2023		0	1	2	1	1	1	3	50,814
Balance, amount at Mar. 31, 2023	(2,855)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 858	$ 475	$ 3,438	139,127	(148,328)	(132)
Common stock warrants exercised, shares									48
Common stock warrants exercised amount	9	0	0	0	0	0	0	0	$ 0	9	0	0
Issuance of common stock for payment of Series D preferred dividends shares									33
Issuance of common stock for payment of Series D preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									36
Issuance of common stock for payment of Series F-2 preferred dividends amount	9	0	0	0	0	0	0	0	$ 0	9	0	0
Conversion of Series F preferred stock to common stock shares									80
Conversion of Series F preferred stock to common stock amount	0	0	0	0	0	0	(20)	0	$ 0	20	0	0
Net Income (Loss)	(1,557)	0	0	0	0	0	0	0	0	0	(1,557)	0
Stock-based compensation	1,119	0	0	0	0	0	0	0	0	1,119	0	0
Accrued preferred dividends	(48)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	(1)	(47)	0
Balance, shares at Jun. 30, 2023		0	1	2	1	1	1	3	51,011
Balance, amount at Jun. 30, 2023	(3,315)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,438	140,291	(149,932)	(132)
Balance, shares at Dec. 31, 2023		0	1	2	1	1	1	0	54,105
Balance, amount at Dec. 31, 2023	(3,806)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,441	140,983	(151,118)	(132)
Issuance of common stock for payment of Series D preferred dividends shares									125
Issuance of common stock for payment of Series D preferred dividends amount	15	0	0	0	0	0	0	0	$ 0	15	0	0
Issuance of common stock for payment of Series E preferred dividends shares									52
Issuance of common stock for payment of Series E preferred dividends amount	8	0	0	0	0	0	0	0	$ 0	8	0	0
Issuance of common stock for payment of Series F preferred dividends shares									445
Issuance of common stock for payment of Series F preferred dividends amount	54	0	0	0	0	0	0	0	$ 0	54	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									236
Issuance of common stock for payment of Series F-2 preferred dividends amount	27	0	0	0	0	0	0	0	$ 0	27	0	0
Issuance of common stock for payment of interest shares									904
Issuance of common stock for payment of interest amount	105	0	0	0	0	0	0	0	$ 1	104	0	0
Stock-based compensation amount	60	0	0	0	0	0	0	0	0	60	0	0
Accrued preferred dividends amount	(88)	0	0	0	0	0	0	0	0	0	(88)	0
Net Income (Loss)	(1,111)	0	0	0	0	0	0	0	$ 0	0	(1,111)	0
Stock-based compensation	60
Settlement of previously accrued professional fees through common stock issuance shares									400
Settlement of previously accrued professional fees through common stock issuance amount	57	0	0	0	0	0	0	0	$ 0	57	0	0
Issuance of warrants with debt amount	12	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	12	0	0
Balance, shares at Jun. 30, 2024		0	1	2	1	1	1	0	56,267
Balance, amount at Jun. 30, 2024	(4,667)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,442	141,320	(152,317)	(132)
Balance, shares at Mar. 31, 2024			1	2	1	1	1		55,614
Balance, amount at Mar. 31, 2024	(4,012)	105	$ 170	$ 439	$ 159	$ 834	$ 838	475	$ 3,441	141,218	(151,559)	(132)
Issuance of common stock for payment of Series D preferred dividends shares									71
Issuance of common stock for payment of Series D preferred dividends amount	6	0	0	0	0	0	0	0	$ 0	6	0	0
Issuance of common stock for payment of Series F-2 preferred dividends shares									72
Issuance of common stock for payment of Series F-2 preferred dividends amount	7	0	0	0	0	0	0	0	$ 0	7	0	0
Issuance of common stock for payment of interest shares									510
Issuance of common stock for payment of interest amount	48	0	0	0	0	0	0	0	$ 1	47	0	0
Stock-based compensation amount	30	0	0	0	0	0	0	0	0	30	0	0
Accrued preferred dividends amount	(49)	0	0	0	0	0	0	0	0	0	(49)	0
Net Income (Loss)	(709)	0	0	0	0	0	0	0	0	0	(709)	0
Issuance of warrants with debt amount	12	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	12	0	0
Balance, shares at Jun. 30, 2024		0	1	2	1	1	1	0	56,267
Balance, amount at Jun. 30, 2024	$ (4,667)	$ 105	$ 170	$ 439	$ 159	$ 834	$ 838	$ 475	$ 3,442	$ 141,320	$ (152,317)	$ (132)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,111)	$ (2,426)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	1	2
Depreciation	5	5
Amortization of debt issuance costs and discounts	50	65
Stock-based compensation	60	1,683
Change in fair value of derivative liability	7	(5)
Amortization of lease right-of-use-asset	42	37
Gain from forgiveness of debt	(33)	(52)
Other non-cash expenses	6	11
Change in operating assets and liabilities:
Accounts receivable	4	(3)
Inventory	0	(25)
Other current assets	52	46
Accounts payable and accrued liabilities	323	(173)
Lease liabilities	(44)	(38)
Deferred revenue	324	(64)
NET CASH USED IN OPERATING ACTIVITIES	(314)	(937)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable	200	0
Payments of debt issuance costs	(17)	0
Payments made on notes payable	(185)	(213)
Proceeds from warrant exercises	0	195
NET CASH USED IN FINANCING ACTIVITIES	(2)	(18)
NET CHANGE IN CASH	(316)	(955)
Cash at beginning of period	591	2,313
CASH AT END OF PERIOD	275	1,358
SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:
Cash paid for interest	21	47
SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Dividends on preferred stock	88	82
Deemed dividends for warrant exchanges	0	65
Warrants issued with debt	12	0
Beneficial conversion feature	6	0
Common stock issued for payment of interest	105	59
Common stock issued for payment of accrued dividends	104	105
Settlement of previously accrued professional fees through common stock issuance	57	0
Accrued payroll liability exchanged for promissory note	87	0
Conversion of Series E preferred shares into common stock	0	5
Conversion of Series F preferred shares into common stock	$ 0	$ 42

ORGANIZATION BACKGROUND AND BAS

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2024
ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2023 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2023. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of June 30, 2024 and December 31, 2023, and the consolidated results of operations and cash flows for the three and six-month periods ended June 30, 2024 and 2023 have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of June 30, 2024, it had an accumulated deficit of approximately $152.1 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision maker is the Chief Executive Officer and acting Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At June 30, 2024, the Company had a negative working capital of approximately $4.7 million, accumulated deficit of $152.3 million, and incurred a net loss including preferred dividends of $1.2 million for the six months then ended. Stockholders’ deficit totaled approximately $4.7 million at June 30, 2024, primarily due to recurring net losses from operations. During the year ended December 31, 2023, the Company received $0.4 million of proceeds from warrant exercises. During the six months ended June 30, 2024, the Company received $0.2 million of proceeds from the issuance of promissory notes payable. The Company will need to continue to raise capital in order to provide funding for its operations and FDA/NMPA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications did not affect net loss, revenues or stockholders’ equity.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements. Accounting Standard Updates A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Concentrations of Credit Risk Trade Receivables Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of June 30, 2024 and December 31, 2023. Inventory Valuation All inventories are stated at the lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. Inventories consisted of the following as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, 2024 2023 Raw materials $ 1,360 $ 1,360 Work-in-progress 46 46 Finished goods 44 44 Inventory reserve (818 ) (818 ) Total inventory $ 632 $ 632 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Depreciation and amortization expense are included in general and administrative expense on the statements of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment consisted of the following as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, 2024 2023 Equipment $ 951 $ 951 Software 634 634 Furniture and fixtures 17 17 Leasehold improvements 12 12 Subtotal 1,614 1,614 Less accumulated depreciation (1,586 ) (1,582 ) Property, equipment and leasehold improvements, net $ 28 $ 32 Depreciation expense related to property and equipment for the three and six months ended June 30, 2024 and 2023 was not material. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three and six months ended June 30, 2024 and 2023. Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 6 – “ Commitments and Contingencies.” Accrued Liabilities Accrued liabilities as of June 30, 2024 and December 31, 2023 are summarized as follows: (in thousands) June 30, 2024 December 31, 2023 Compensation $ 356 $ 401 Professional fees 95 216 Interest 143 188 Vacation 29 27 Preferred dividends 210 228 Other accrued expenses 7 8 Total $ 840 $ 1,068 Stock Subscription Payable Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet. Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company’s revenues do not require significant estimates or judgments and are recognized when control of the promised goods or services is transferred to the Company’s customers, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. Revenue is measured as the amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company does not offer returns, discounts, loyalty programs or other sales incentive programs that are material to revenue recognition. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. Deferred revenue totaled $747,780, $424,225, and $509,101 as of June 30, 2024, December 31, 2023 and December 31, 2022, respectively. Significant Customers As of June 30, 2024, trade receivables of $2,047 (net of the allowance for credit losses of $450) were attributed to one customer. As of December 31, 2023, accounts receivable of $7,442 (net of the allowance for credit losses of $1,500) were attributed to two customers. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed for an extension for its 2023 federal and state corporate tax returns. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At June 30, 2024, the Company had approximately $66.4 million of net operating losses carryforward available, $3.8 million of which will expire on December 31, 2024. The remaining net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes or binomial option pricing models. Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. During the six months ended June 30, 2024, the Company recognized $29,673 of expense related to stock options and $30,932 of expense for warrants issued to a director. During the six months ended June 30, 2023, the Company recognized $206,306 of expense related to stock options, $116,000 of expense for stock issued to a director and $1,361,143 of expense for warrants issued to consultants and executives. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense. Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures,” · Level 1: · Level 2: · Level 3: An asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820: · Market approach: · Cost approach: · Income approach: The Company believes its valuation methods are appropriate and consistent with other market participants, however the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	6 Months Ended
	Jun. 30, 2024
STOCKHOLDERS' DEFICIT:
STOCKHOLDERS' DEFICIT	3. STOCKHOLDERS’ DEFICIT Common Stock The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of June 30, 2024 and December 31, 2023, 56,266,661 and 54,105,101 shares of common stock were issued and outstanding, respectively. During the six months ended June 30, 2024, the Company issued 2,161,560 shares of common stock, as summarized below: Number of Shares Issuance of common stock for payment of Series D preferred dividends 125,505 Issuance of common stock for payment of Series E preferred dividends 52,332 Issuance of common stock for payment of Series F preferred dividends 444,621 Issuance of common stock for payment of Series F-2 preferred dividends 235,544 Issuance of common stock for payment of interest 903,558 Issuance of common stock to consultants 400,000 Total common stock issued during the six months ended June 30, 2024 2,161,560 Summary table of common stock transactions: Shares outstanding at December 31, 2023 54,105,101 Common shares issued during the six months ended June 30, 2024 2,161,560 Shares outstanding at June 30, 2024 56,266,661 Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $0.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C Preferred Stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At June 30, 2024 and December 31, 2023, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C Preferred Stock would convert into approximately 2,000 shares of the Company’s common stock; for a total of 572,000 shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C Preferred Stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of June 30, 2024 and December 31, 2023. Upon conversion of the Series C Preferred Stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At June 30, 2024 and December 31, 2023, the “make-whole payment” for a converted share of Series C Preferred Stock would convert to 200 shares of the Company’s common stock. The Series C Preferred Stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049.25 shares were issued and outstanding at June 30, 2024 and December 31, 2023. The C1 Convertible Preferred Stock has a conversion price of $0.50 per share, such that each share would convert into approximately 2,000 shares of the Company’s common stock, for a total of 2,098,500 shares of common stock. The Series C1 Preferred Stock has terms that are substantially the same as the Series C Preferred Stock, except that the Series C1 Preferred Stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C Preferred Stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Convertible Preferred Stock, including the chairman of the Company’s board of directors, the former Chief Operating Officer (now the Chief Executive Officer) and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Convertible Preferred Stock. In total, for 3,262.25 shares of Series C1 Convertible Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Convertible Preferred Stock. At June 30, 2024 and December 31, 2023, there were 2,700 shares outstanding, each with a conversion price of $0.50 per share, such that each share of Series C2 preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total of 5,400,000 common shares. The terms of the Series C2 Convertible Preferred Stock are substantially the same as the Series C1 shares, except that (i) shares of Series C1 Convertible Preferred Stock were not convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Convertible Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Convertible Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The board designated 6,000 shares of preferred stock as Series D Preferred Stock, 438 of which remained outstanding as of June 30, 2024 and December 31, 2023. On January 8, 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer (now the Chief Executive Officer) and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 shares of common stock, 1,526,000 common stock warrants exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 shares of common stock. The Series D Preferred Stock have cumulative dividends at the rate per share of 10% per annum. Each share of Series D Preferred Stock has a par value of $0.001 per share and a stated value equal to $750. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the six months ended June 30, 2024, the Company issued 125,505 shares of common stock for the payment of accrued Series D Preferred Stock dividends. As of June 30, 2024, and December 31, 2023, the Company had accrued dividends for the Series D Preferred Stock of $8,360. Series E Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 883 of which remained outstanding as of June 30, 2024 and December 31, 2023. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a stated value equal to $1,000, subject to the increase set forth in its Certificate of Designation. Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, at the option of the Company, shares of common stock. During the six months ended June 30, 2024, the Company issued 52,332 shares of common stock for payment of accrued Series E Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends of $57,592 and $30,272 for the Series E Preferred Stock, respectively. Series F Convertible Preferred Stock The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,006 of which remained outstanding as of June 30, 2024 and December 31, 2023. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 shares of common stock. The Series F Preferred Stock is entitled to cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F Preferred Stock is $1,000. Each share of Series F Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred Stock is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate stated value then outstanding plus accrued but unpaid dividends. During the six months ended June 30, 2024, the Company issued 444,621 shares of common stock for the payment of annual Series F Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends for Series F preferred shares of $15,761 and $46,108, respectively. Series F-2 Convertible Preferred Stock The Company was oversubscribed for its Series F Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Preferred Stock with substantially the same terms as the Series F Preferred Stock. The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 520 of which were issued and outstanding as of June 30, 2024 and December 31, 2023. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors. In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred share is convertible into 4,000 shares of common stock. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F-2 Preferred Stock is $1,000. Each share of Series F-2 Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred Stock, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the six months ended June 30, 2024, the Company issued 235,544 shares of common stock for the payment of annual Series F-2 Preferred Stock dividends. As of June 30, 2024 and December 31, 2023, the Company had accrued dividends for Series F-2 preferred shares of $7,918 and $23,579, respectively. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the six months ended June 30, 2024 and 2023: Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2023 28,584,580 $ 0.50 Warrants issued 1,000,000 0.30 Warrants expired (761,500 ) 0.37 Outstanding, June 30, 2024 28,823,080 $ 0.50 Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2022 35,586,980 $ 0.46 Warrants issued 5,873,750 0.25 Warrants exchanged (1,025,000 ) 0.25 Warrants expired (9,478,200 ) 0.30 Warrants exercised (973,750 ) 0.20 Outstanding, June 30, 2023 29,983,780 $ 0.49 During the six months ended June 30, 2024 and 2023, the Company issued 900,000 warrants to Richard Blumberg, a related party, pursuant to a consulting agreement. See Note 6, “Commitments and Contingencies” During the six months ended June 30, 2024, the Company issued 100,000 warrants in conjunction with the issuance of a $100,000 note payable to an unaffiliated third party. See Note 7, “Notes Payable” Expected term (years) 4.0 Volatility 389.2 % Risk-free interest rate 4.4 % Dividend yield 0.0 % On May 14, 2023, the Compensation Committee of the Company’s Board of Directors approved the issuance of 4,000,000 common stock warrants to Mark Faupel, upon his appointment to the Company’s Board as President and Chief Executive Officer on March 10, 2023. The warrants, which have a strike price of $0.25, are fully vested and will expire on May 13, 2028. During the six months ended June 30, 2023, the Company recorded approximately $679,959 of stock-based compensation expense attributed to the warrants. On May 14, 2023, the Compensation Committee of the Company’s Board of Directors also approved the issuance of 4,000,000 common stock warrants to Mark Faupel, 2,500,000 of which will be vested upon receipt by the Corporation of an Approval Letter from the U.S. Food and Drug Administration for the LuViva Advanced Cervical Scan and 1,500,000 of which will be vested upon receipt by the Corporation of an Approval Letter or equivalent from the Chinese National Medical Products Administration for the LuViva Advanced Cervical Scan. The warrants, which have a strike price of $0.40, will expire five years after they are exercisable with a maximum term of 10 years from issuance. As of June 30, 2023, the Company has concluded it is not probable that the performance conditions related to the warrants will be achieved, and as a result no compensation expense related to the warrants has been recorded. During the six months ended June 30, 2023, the Company entered into various agreements with holders of the Company’s $0.25 strike price warrants, pursuant to which each holder separately agreed to exchange 1,025,000 common stock warrants with a strike price of $0.25 for 973,750 common stock warrants with a strike price of $0.20. The Company received approximately $194,750 from the holders for the exercise of the 973,750 warrants. The Company measured the effect of the exchange as the excess of fair value of the exchanged instruments over the fair value of the original instruments and recorded a deemed dividend of approximately $65,296. During the six months ended June 30, 2023, management estimated the fair value of the warrants issued utilizing the Black-Scholes Option Pricing model with the following weighted-average assumptions: Expected term (years) 3.9 Volatility 290.6 % Risk-free interest rate 3.7 % Dividend yield 0.0 %

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2024
STOCK OPTIONS
STOCK OPTIONS	4. STOCK OPTIONS The Company’s Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The aggregate number of common shares that may be issued or reserved pursuant to stock option or other awards under the plan may not exceed 2,500,000 common shares. During the six months ended June 30, 2024 and 2023, the Company recognized expense for stock options of $29,673 and $206,306, respectively. There was no stock option activity during the six months ended June 30, 2024. On February 10, 2023, the Company granted 925,000 stock options to employees, executives and directors of the Company. The stock options, which have exercise prices of $0.2629, will expire on February 9, 2033. One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023. On March 7, 2023, the Company granted 100,000 stock options, which have exercise prices of $0.27 and will expire on March 6, 2033, to Alan Grujic, upon appointing him to the Board of Directors. One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023. The following tables summarize the Company’s stock option activity and related information for the six months ended June 30, 2024 and 2023: Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of December 31, 2023 2,338,636 $ 0.41 6.5 years $ - Options outstanding as of June 30, 2024 2,338,636 $ 0.41 6.1 years $ - Options exercisable as of June 30, 2024 1,980,114 $ 0.43 5.6 years $ - Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of December 31, 2022 1,500,000 $ 0.49 7.5 years $ - Options granted 1,025,000 $ 0.26 Options forfeited (186,364 ) $ 0.31 Options outstanding as of June 30, 2023 2,338,636 $ 0.41 7.1 years $ - Options exercisable as of June 30, 2023 1,755,114 $ 0.45 6.2 years $ - The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of June 30, 2024 and the exercise price, multiplied by the number of options. As of June 30, 2024, there was $94,578 of unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.75 years. The weighted-average fair value of awards granted was nil and $0.26 during the six months ended June 30, 2024 and 2023, respectively. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The Black-Scholes option pricing model and the following weighted-average assumptions were used to estimate the fair value of awards granted during the six months ended June 30, 2023: Expected term (years) 10.0 Volatility 366.4 % Risk-free interest rate 3.8 % Dividend yield 0.00 On March 3, 2023, Dr. Gene Cartwright retired from his position as President and Chief Executive Officer of the Company and as a member of the Board. Upon his departure, Mr. Cartwright forfeited 186,364 unvested stock options. On May 2, 2023, the Company’s Board of Directors approved an extension of the expiration date of Mr. Cartwright’s vested options to June 1, 2025. Management measured the modified stock option award using the Black-Scholes option pricing model and recorded expense of $59,216 during the six months ended June 30, 2023, representing the excess fair value of the modified award over the original award. Management estimated the fair value of the modified award using the Black-Scholes option pricing model and the following assumptions: Expected term (years) 2.0 Volatility 182.8 % Risk-free interest rate 4.0 % Dividend yield 0.0 %

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS	6 Months Ended
	Jun. 30, 2024
LITIGATION AND CLAIMS
LITIGATION AND CLAIMS	5. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of June 30, 2024, and December 31, 2023, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	6. COMMITMENTS AND CONTINGENCIES Operating Leases Our corporate offices, which also comprise our administrative, research and development, marketing and production facilities, are located on a 12,835 square foot leased property. Total operating lease cost recognized for this lease was unchanged from the prior period and was $27,351 and $54,702 for the three and six months ended June 30, 2024, respectively. The below table presents total operating lease right-of-use assets and lease liabilities as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31 2024 2023 Operating lease right-of-use assets $ 185 $ 227 Operating lease liabilities $ 203 $ 246 The table below presents the maturities of operating lease liabilities as of June 30, 2024: (in thousands) Operating Lease Payments 2024 (remaining) 58 2025 118 2026 50 Total future lease payments 226 Less: discount (23 ) Total lease liabilities $ 203 The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities as of June 30, 2024 and December 31, 2023 (in thousands) June 30, 2024 December 31, 2023 Weighted average remaining lease term (years) 1.9 2.4 Weighted average discount rate 11.4 % 11.4 % Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each cervical guide that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company agreed to issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the scheduled issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020. As of June 30, 2024, unrecognized consulting expense associated with the agreement was nil and 2,500,000 of the warrants had been issued, of which 1,750,000 were issued to Mr. Blumberg and 750,000 were issued to non-related parties. During the six months ended June 30, 2023, the Company entered into an agreement with Mr. Blumberg to exchange 875,000 of the outstanding warrants for 831,250 warrants with a strike price of $0.20, which were exercised during the first quarter of 2023. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for the following: (1) 3,600,000 3-year warrants with exercise prices ranging from $0.30 - $0.60, and (2) 1,600,000 common stock shares. On September 30, 2021, the Company and Mr. Blumberg entered into an amended agreement, pursuant to which issuance of the warrants and common shares became predicated on the Company obtaining financing or a series of financings resulting in minimum receipts of at least $1.0 million. Upon receipt of the funds, the Company agreed to issue the common shares and warrants owed to Mr. Blumberg in four equal tranches, to be issued every six months, beginning six months after the financing transaction. On November 11, 2022, the Company and Mr. Blumberg entered into an amended agreement, upon which the exercise prices of the warrants were changed to $0.30. The Company estimated the fair value of the modified warrants using the Black-Scholes option pricing model and the following assumptions: Expected term (years) 3.0 Volatility 108.7 % Risk-free interest rate 4.3 % Dividend yield 0.0 % During the six months ended June 30, 2024 and 2023, the Company issued 900,000 warrants to Mr. Blumberg, pursuant to the agreement, and recognized expense of nil and $590,840, respectively. Total unrecognized expense for the warrants was nil as of June 30, 2024. During the six months ended June 30, 2024 and 2023, the Company recognized $7,425 and $111,833 of expense for the shares of common stock due to Mr. Blumberg, respectively. As 400,000 shares had not been issued as of June 30, 2024, the Company estimated the total amount of expense for the future issuances using the closing price of the Company’s stock as of June 30, 2024. On August 24, 2022, the Company entered into an agreement with Ironstone Capital Corp. and Alan Grujic (the “Advisory Group”) whereby the Advisory Group agreed to perform marketing and investor relations services over a term of twelve months, commencing on the closing of a financing of at least $2.5 million. In consideration for these services, the Company issued 800,000 warrants (“first tranche of warrants”) with an exercise price of $0.50 to Mr. Grujic, which were due within 10 business days of closing the financing transaction (the “Transaction”) that took place in September 2022. In the event the Company’s 20 trading day variable weighted average price (“VWAP”) exceeds $1.00 within one year of the closing of the financing, the Company would have issued 600,000 warrants (“second tranche of warrants”) with an exercise price of $0.75 to Mr. Grujic. In the event the Company’s 20 trading day VWAP exceeds $1.50 within two years of the closing of the financing, the Company will issue an additional 600,000 warrants (“third tranche of warrants”) to Mr. Grujic. Once issued, the warrants vest immediately and will expire two years from the date of issuance. If the Company’s U.S. clinical study is not completed and filed with the U.S. FDA or if the Chinese NMPA (formerly Chinese FDA) approval is not granted by each due date for reaching each respective pricing milestone, then the due date for reaching each milestone shall be extended by six months. As of June 30, 2024, the deadline to achieve the stock price of $1.50 has passed and the second tranche warrants will therefore not be issued. Pursuant to the agreement, the Company also agreed to pay the Advisory Group $2,000 per month for 12 months, starting the month after the closing of the Transaction. Subsequently, the agreement was amended to extend the term of the agreement to September of 2024. The Company estimated the fair value of the first tranche warrants issued in September 2022 using the Black-Scholes option pricing model with the following assumptions: Expected term (years) 2.0 Volatility 173.0 % Risk-free interest rate 3.4 % Dividend yield 0.0 % Expense related to the first tranche of warrants was recognized in prior years. Unrecognized expense related to the first tranche warrants was nil as of June 30, 2024. The Company estimated the fair value of the second tranche warrants using the Binomial Lattice model with the following assumptions: Expected term (years) 1.0 Volatility 144.4 % Risk-free interest rate 3.6 % Dividend yield 0.0 % The Company recognized expense for the second tranche of warrants of nil and $29,706 during the three months ended June 30, 2024 and 2023, respectively. The Company recognized expense for the second tranche of warrants of nil and $59,412 during the six months ended June 30, 2024 and 2023, respectively. Unrecognized expense for the third tranche of warrants was nil as of June 30, 2024. The Company estimated the fair value of the third tranche warrants using the Binomial Lattice model with the following assumptions: Expected term (years) 2.0 Volatility 172.1 % Risk-free interest rate 3.6 % Dividend yield 0.0 % The Company recognized expense for the third tranche of warrants of $15,466 during the three months ended June 30, 2024 and 2023. The Company recognized expense for the third tranche of warrants of $30,932 during the six months ended June 30, 2024 and 2023. Unrecognized expense for the third tranche of warrants was $10,311 as of June 30, 2024. Other Commitments On July 24, 2019, the Company agreed to grant Shandong Yaohua Medical Instrument Corporation (“SMI”) (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the terms and conditions described below. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 shares of common stock. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides, then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On August 12, 2021, the Company executed an amendment to its agreement with SMI. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. On March 3, 2023, the Company entered into a third amendment with SMI pursuant to which the Company extended the deadline for SMI to achieve commercialization of LuViva in China to April 30, 2024. On February 17, 2024, the Company entered into a fourth amendment to the agreement with SMI. Under the terms of the amended agreement, SMI agreed to pay the Company $531,100 on or prior to March 15, 2024. On March 18, 2024, SMI, through SMI’s authorized distribution partner, initiated a wire payment of $330,000 in partial satisfaction of $531,100 owed to the Company. The payment was received by the Company on March 20, 2024. As the full payment was not received by March 15, 2024, the Company had the right to terminate the agreement with two weeks’ notice to SMI, however the Company did not exercise this option. The amended agreement also provides for a timeline for the Company to deliver inventory during 2024, including LuViva devices and components, as well as approximately 1,640,000 RFID chips. In consideration, SMI agreed to pay a total of $4.4 million during 2024, including the payment due on March 15, 2024. On March 27, 2024, the parties entered into a Standstill Agreement (the “Standstill Agreement”). The parties agreed that SMI will make a nonrefundable payment of $100,000 to the Company prior to March 31, 2024. In exchange, the Company will not initiate any legal proceedings, including but not limited to filing a lawsuit, obtaining a judgement, or enforcing any security interest, as related to the March shortfall in payments of $201,100, until April 30, 2024. Upon paying $100,000, SMI will have the option to extend the Standstill Agreement until June 15, 2024 by making a nonrefundable payment to the Company of $150,000. One additional payment of $150,000 may be made to extend the standstill rights until July 30, 2024, if mutually agreed upon. If SMI is unable to make the payments pursuant to the Standstill Agreement, the Company agreed to seek loans on behalf of SMI to cover the payments. SMI agreed to reimburse the Company for these loans along with all expenses associated with them within three months of the loans being issued as long as the loans are used solely for (1) parts for LuViva devices to be used by SMI for marketing and promotional activities, or (2) labor or consulting fees connected to providing parts, assemblies of devices or disposables to SMI. Additionally, SMI confirmed its commitment to make payments to GTI of at least $4.0 million during 2024 and as part of this commitment will make payments of $200,000 and $500,000 by the end of May 2024 and July 2024, respectively, to ensure that the program commercialization proceeds according to schedule. On April 26, 2024, the parties extended the Standstill Agreement (“Standstill Extension”) until July 30, 2024, contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545. The other terms from the Amendment and Standstill Agreement remained intact. The Company and SMI executed an extension to the Standstill Agreement (the “Second Standstill Extension”) subsequent to June 30, 2024. Please see Note 12, “Subsequent Events Contingencies The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2024
NOTES PAYABLE
NOTES PAYABLE	7. NOTES PAYABLE On June 28, 2024, the Company issued a promissory note totaling $100,000 to an unaffiliated third party. The promissory note matures on January 1, 2025 and will accrue total interest of $10,000. Monthly payments of $20,000 are due on the note, beginning August 1, 2024 until December 1, 2024, while the interest payment is due on or before January 1, 2025. The promissory note may be prepaid in full or in part without penalty or premium. The holder of the promissory note also received 100,000 common stock purchase warrants, which will have an exercise price of $0.25 and will expire on July 1, 2028. The warrants, which had an estimated fair value of $11,998, were recorded as a discount on the note payable. On April 15, 2024, the Company entered into an exchange agreement with a former employee, whereby the former employee agreed to exchange outstanding amounts due to him for deferred compensation in the amount of $81,768 for an $87,162 promissory note dated April 15, 2024. Beginning on May 5, 2024, monthly payments of $2,000 are due on the note until its maturity date. The promissory note, which accrues interest at a rate of 6% per annum, matures on May 5, 2028. The total balance of the promissory note was $83,162 as of June 30, 2024, of which $24,000 is presented in “Short-term notes payable” on the consolidated balance sheets and $59,162 is included in “Long-term notes payable.” On July 4, 2023, the Company entered into a premium finance agreement to finance its insurance policies totaling $129,073. Monthly payments of $12,041 are due on the note, including interest incurred at a rate of 7.9%. The note, which matured on May 4, 2024, had an outstanding balance of nil and $59,422 as of June 30, 2024 and December 31, 2023, respectively. The following table summarizes short-term notes payable (in thousands): Short-term notes payable June 30, 2024 December 31, 2023 Short-term promissory note $ 100 $ - Current portion of long-term promissory note 24 - Premium Finance (insurance) - 59 Debt Discount (12 ) - Short-term notes payable $ 112 $ 59

CONVERTIBLE DEBT

CONVERTIBLE DEBT	6 Months Ended
	Jun. 30, 2024
CONVERTIBLE DEBT
CONVERTIBLE DEBT	8. CONVERTIBLE DEBT 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which matured on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into shares of common stock at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit included 1,000 common stock warrants with an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into shares of common stock, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into shares of common stock at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the shares of common stock is $1.50 per share of common stock or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering shares of common stock to the holders of Convertible Debentures at a deemed price of $0.50 per share of common stock that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At June 30, 2024 and December 31, 2023, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total accrued interest was $24,860 and $58,494, respectively. After the May 17, 2024 maturity date, the interest rate increased to the default rate of 18.0%. The bond payable discount and unamortized debt issuance costs as of June 30, 2024 and December 31, 2023 are presented below (in thousands): Senior Secured Convertible Debenture June 30, 2024 December 31, 2023 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Unamortized debt issuance costs - (12 ) Debt Discount - (38 ) Senior Unsecured Convertible Debenture $ 1,130 $ 1,080 As of June 30, 2024, the balance of the Senior Unsecured Convertible Debenture is included in “Short-term convertible notes payable in default” within the condensed consolidated balance sheets. As of December 31, 2023, the balance of the Senior Unsecured Convertible Debenture is included in “Short-term convertible notes payable” within the condensed consolidated balance sheets. 1800 Diagonal Lending Note On June 11, 2024, the Company entered into a securities purchase agreement and contingently convertible note with 1800 Diagonal Lending LLC (“Diagonal Lending”). The convertible note issued to Diagonal Lending had a total principal balance of $100,050 and an original issue discount of $13,050. The note, which will accrue total interest of $14,007, will mature on April 15, 2025. A payment of $57,029 is due on the note on December 15, 2024. The remaining balance due, including accrued interest, will be paid in monthly payments of $14,257 from January 15, 2025 through April 15, 2025. The note may be prepaid within 120 days of issuance for a discount of 2.0 -3.0 % of the principal and accrued interest due. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note will become immediately due and payable in an amount equal to 150.0% times the sum of the then outstanding principal, accrued interest and default interest. In an event of default, the unpaid portion of the note and accrued interest is convertible into shares of common stock at a conversion rate equal to the variable conversion price. The variable conversion price is equal to the lowest closing price of our common stock during the ten days prior to the conversion date multiplied by 65.0%. The Company assessed this embedded conversion feature and determined that it is not considered clearly and closely related to the host note, and therefore meets the definition of a derivative. Therefore, this embedded conversion feature is required to be bifurcated from the note and accounted for separately as a derivative liability. The Company estimated the fair value of the combined derivative liability as of June 11, 2024, which was recorded as a liability and as a discount net against the subordinated convertible notes. The Company is required to remeasure the combined derivative liability to its then fair value at each subsequent balance sheet date, through an adjustment to current earnings (see Note 11 for further details on the Company’s fair value measurement). At June 30, 2024, the balance due on the note was $100,000 and total accrued interest was $1,166. The note payable discount, unamortized debt issuance costs and unamortized debt discount (including the beneficial conversion feature) as of June 30, 2024 and December 31, 2023 is presented below (in thousands): June 30, 2024 December 31, 2023 Short-term convertible promissory note $ 100 $ - Unamortized debt issuance costs (4 ) - Debt Discount (12 ) - Beneficial conversion feature (5 ) - 1800 Diagonal Lending Convertible Note $ 79 $ - Auctus Convertible Note On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus Fund, LLC (“Auctus’). The convertible note issued to Auctus was for a total of $2.4 million. The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied. On September 1, 2022, the Company agreed to exchange certain debt and equity owned by Auctus pursuant to an Exchange Agreement between the Company and Auctus (the “Exchange Agreement”). Immediately prior to the Exchange Agreement, Auctus held $1,228,183 of debt, including an early prepayment penalty of $350,000, default premiums of $281,256, and $91,555 in interest payable. Auctus agreed to reduce the amount owed to $710,911 and to revert the May 27, 2020 note to its original term. Additionally, Auctus agreed to exchange 8,775,000 warrants that were priced between $0.15 and $0.20 and the $350,000 prepayment penalty for 3,900,000 shares of common stock, warrants to purchase 3,900,000 shares of common stock at $0.50 per share and warrants to purchase 3,900,000 shares of common stock at $0.65 per share (the “Exchange”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. During 2024, Auctus agreed to apply the payments to the principal portion of the debt before applying the funds to the accrued interest. As a result, management has reclassified a portion of the current and prior period outstanding debt to the accrued interest as described below. The total outstanding balance of the convertible note was $15,000 and $25,000 as of June 30, 2024 and December 31, 2023, respectively. The balances are included within “Short-term convertible notes payable” on the condensed consolidated balance sheets. Total accrued interest on the Auctus convertible note was $115,646 and $121,995 as of June 30, 2024 and December 31, 2023, respectively.

RELATED PARTY DEBT

RELATED PARTY DEBT	6 Months Ended
	Jun. 30, 2024
RELATED PARTY DEBT
RELATED PARTY DEBT	9. RELATED PARTY DEBT On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum. On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement. Pursuant to this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, the maturity date was February 18, 2023, and the interest rate was 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, the maturity date was February 18, 2023, and the interest rate was 6.0%. Additionally, the Company exchanged $100,000 and $85,000 of the balances owed to Dr. Cartwright and Dr. Faupel for 100 and 85 shares of Series F-2 Preferred Stock, respectively. On February 18, 2023, the Company amended the terms of the promissory notes held by Mark Faupel and Gene Cartwright. Under the terms of the new agreements, the promissory notes will mature on February 18, 2025. The tables below summarize the outstanding balance of long-term debt owed to Dr. Faupel and Dr. Cartwright (in thousands): For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2023 57 Balance outstanding at December 31, 2023 $ 179 Interest accrued through June 30, 2024 5 Balance outstanding at June 30, 2024 $ 184 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2023 93 Payments on outstanding debt (25 ) Balance outstanding at December 31, 2023 $ 287 Interest accrued through June 30, 2024 7 Balance outstanding at June 30, 2024 $ 294 On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Stock (convertible into 200,000 shares of common stock), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,600 for four years, with the first payment due on March 15, 2022. The effective interest rate of the note is 6.18%. During the three and six months ended June 30, 2024, Mr. Fowler forgave $16,401 and $33,060 of the outstanding balance of deferred compensation, respectively. During the three and six months ended June 30, 2023, Mr. Fowler forgave $17,450 and $35,171 of the outstanding balance of deferred compensation, respectively. As of June 30, 2024, Mr. Fowler may forgive up to $96,276 of the remaining deferred compensation if the Company complies with the repayment plan described above. The reductions in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of June 30, 2024 and December 31, 2023, the outstanding principal amount owed on the note was $63,731 and $82,945, respectively. Future debt obligations at June 30, 2024 for debt owed to related parties is as follows: Year Amount (in thousands) 2024 (remaining) 21 2025 519 2026 3 Total $ 543

INCOME (LOSS) PER SHARE OF COMM

INCOME (LOSS) PER SHARE OF COMMON STOCK	6 Months Ended
	Jun. 30, 2024
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
INCOME (LOSS) PER SHARE OF COMMON STOCK	10. INCOME (LOSS) PER SHARE OF COMMON STOCK Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series C-1, Series C-2, Series D, Series E, Series F and Series F-2 convertible preferred stock, convertible debt, convertible preferred dividends, warrants and stock options convertible into common stock shares. During a period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt and preferred stock are anti-dilutive. For the three and six months ended June 30, 2024 and 2023, all stock options, convertible preferred stock, convertible debt and warrants were anti-dilutive and were therefore excluded from the computation of diluted loss per share. At June 30, 2024 and 2023, these instruments were convertible into 53,674,649 and 54,482,496 common shares, respectively. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data): June 30, 2024 2023 Net loss (1,199 ) (2,573 ) Basic weighted average number of shares outstanding 55,368 50,138 Net loss per share (basic) (0.02 ) (0.05 ) Diluted weighted average number of shares outstanding 55,368 50,138 Net loss per share (diluted) (0.02 ) (0.05 )

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2024
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	11. FAIR VALUE MEASUREMENTS The convertible notes payable derivative liability is considered a Level 3 measurement, due to the significant unobservable inputs in the valuation, which are based on a forecast of the Company’s future stock performance and, as the note payable is contingently convertible upon an event of default, management’s estimate of the likelihood and timing of conversion. Based on the terms and provisions of the Diagonal Lending note payable, management built a pricing simulation that predicts the Company’s future stock prices using historical volatility. Our model is designed to utilize the Company’s best estimates of the timing and likelihood of a conversion of the note payable to calculate the variable conversion price as of the future conversion date. The key inputs to the valuation model that was utilized to estimate the fair value of the bifurcated conversion option included: · The forecasted future stock prices were determined using historical stock prices and the Company’s equity volatility. · The expected conversion price was determined using the forecast and the contractual term of the convertible note agreement. · The probability of an event of default and timing of a future conversion are based on management’s best estimate of the future settlement of the convertible note. The following tables present the fair value of the bifurcated conversion option: Fair Value at June 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Diagonal Lending $100,050 promissory note - - 13 13 Total short-term liabilities at fair value $ - $ - $ 13 $ 13 Derivative financial instruments and changes thereto recorded in the six months ended June 30, 2024 and 2023 include the following: Six Months Ended June 30, 2024 2023 Balance, beginning of period $ - $ (5 ) Inception of derivative liability 5 Change in fair value during the period 7 5 Balance, end of period $ 12 $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Issuances of Promissory Notes and Related Warrants On July 22, 2024, we issued a $62,100 convertible promissory note to Diagonal Lending. The convertible promissory note, which had an original issue discount of $8,100, will mature on May 30, 2025 and will accrue total interest of $8,694. A payment of $35,397 will be due on January 30, 2025. The remaining balance, including the accrued interest, will be paid in monthly installments of $8,849 beginning February 28, 2024 and ending on the maturity date. The remaining terms of the convertible promissory note are identical to the June 11, 2024 convertible promissory note disclosed within Note 8, “Convertible Debt,” On July 23, 2024, we issued a $50,000 promissory note to an unaffiliated third party (the “Holder”). The promissory note, which will incur total interest of $5,000, will mature on February 1, 2025. Monthly payments of $10,000 are due beginning September 1, 2024 and ending January 1, 2025. The $5,000 interest payment is due on February 1, 2025. With the Holder’s permission, the promissory note may be prepaid in full or in part without penalty or premium. In connection with the promissory note, we issued 60,000 common stock warrants with a strike price of $025. The warrants will expire on July 31, 2028. Subsequent to June 30, 2024, we issued three $25,000 promissory notes to our directors. The promissory notes mature in one year and accrue interest at an annual rate of 9.0%. In connection with the promissory notes, we issued 75,000 common stock warrants to our directors. The warrants, which have a strike price of $0.25, will expire four years after the issuance date. Issuances of Common Stock Subsequent to June 30, 2024, we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense. Second Extension of Standstill Amendment with SMI Subsequent to June 30, 2024, SMI payments due on July 31, 2024 remained unpaid. On July 31, 2024, the Company and SMI jointly agreed to extend the Standstill Agreement until August 16, 2024, upon which a longer-term agreement is expected to be executed.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.
Accounting Standard Updates	A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Concentrations of Credit Risk	The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was nil and $156,112 as of June 30, 2024 and December 31, 2023, respectively.
Trade Receivables	Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of June 30, 2024 and December 31, 2023.
Inventory Valuation	All inventories are stated at the lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. Inventories consisted of the following as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, 2024 2023 Raw materials $ 1,360 $ 1,360 Work-in-progress 46 46 Finished goods 44 44 Inventory reserve (818 ) (818 ) Total inventory $ 632 $ 632 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Depreciation and amortization expense are included in general and administrative expense on the statements of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment consisted of the following as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, 2024 2023 Equipment $ 951 $ 951 Software 634 634 Furniture and fixtures 17 17 Leasehold improvements 12 12 Subtotal 1,614 1,614 Less accumulated depreciation (1,586 ) (1,582 ) Property, equipment and leasehold improvements, net $ 28 $ 32 Depreciation expense related to property and equipment for the three and six months ended June 30, 2024 and 2023 was not material.
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three and six months ended June 30, 2024 and 2023.
Leases	A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 6 – “ Commitments and Contingencies.”
Accrued Liabilities	Accrued liabilities as of June 30, 2024 and December 31, 2023 are summarized as follows: (in thousands) June 30, 2024 December 31, 2023 Compensation $ 356 $ 401 Professional fees 95 216 Interest 143 188 Vacation 29 27 Preferred dividends 210 228 Other accrued expenses 7 8 Total $ 840 $ 1,068
Stock Subscription Payable	Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.
Revenue Recognition	ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company’s revenues do not require significant estimates or judgments and are recognized when control of the promised goods or services is transferred to the Company’s customers, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. Revenue is measured as the amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company does not offer returns, discounts, loyalty programs or other sales incentive programs that are material to revenue recognition. The Company is not party to contracts that include multiple performance obligations or material variable consideration.
Contract Balances	The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. Deferred revenue totaled $747,780, $424,225, and $509,101 as of June 30, 2024, December 31, 2023 and December 31, 2022, respectively.
Significant Customers	As of June 30, 2024, trade receivables of $2,047 (net of the allowance for credit losses of $450) were attributed to one customer. As of December 31, 2023, accounts receivable of $7,442 (net of the allowance for credit losses of $1,500) were attributed to two customers.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed for an extension for its 2023 federal and state corporate tax returns. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At June 30, 2024, the Company had approximately $66.4 million of net operating losses carryforward available, $3.8 million of which will expire on December 31, 2024. The remaining net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes or binomial option pricing models.
Stock Based Compensation	The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation – Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. During the six months ended June 30, 2024, the Company recognized $29,673 of expense related to stock options and $30,932 of expense for warrants issued to a director. During the six months ended June 30, 2023, the Company recognized $206,306 of expense related to stock options, $116,000 of expense for stock issued to a director and $1,361,143 of expense for warrants issued to consultants and executives.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.
Fair Value Measurements	ASC 820, “ Fair Value Measurements and Disclosures,” · Level 1: · Level 2: · Level 3: An asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820: · Market approach: · Cost approach: · Income approach: The Company believes its valuation methods are appropriate and consistent with other market participants, however the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Schedule of Inventory valuation	(in thousands) June 30, December 31, 2024 2023 Raw materials $ 1,360 $ 1,360 Work-in-progress 46 46 Finished goods 44 44 Inventory reserve (818 ) (818 ) Total inventory $ 632 $ 632
Schedule of Property and equipment	(in thousands) June 30, December 31, 2024 2023 Equipment $ 951 $ 951 Software 634 634 Furniture and fixtures 17 17 Leasehold improvements 12 12 Subtotal 1,614 1,614 Less accumulated depreciation (1,586 ) (1,582 ) Property, equipment and leasehold improvements, net $ 28 $ 32
Schedule of Accrued liabilities	(in thousands) June 30, 2024 December 31, 2023 Compensation $ 356 $ 401 Professional fees 95 216 Interest 143 188 Vacation 29 27 Preferred dividends 210 228 Other accrued expenses 7 8 Total $ 840 $ 1,068

STOCKHOLDERS DEFICIT (Tables)

STOCKHOLDERS DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2024
STOCKHOLDERS' DEFICIT:
Schedule of Common stock issued	Number of Shares Issuance of common stock for payment of Series D preferred dividends 125,505 Issuance of common stock for payment of Series E preferred dividends 52,332 Issuance of common stock for payment of Series F preferred dividends 444,621 Issuance of common stock for payment of Series F-2 preferred dividends 235,544 Issuance of common stock for payment of interest 903,558 Issuance of common stock to consultants 400,000 Total common stock issued during the six months ended June 30, 2024 2,161,560 Summary table of common stock transactions: Shares outstanding at December 31, 2023 54,105,101 Common shares issued during the six months ended June 30, 2024 2,161,560 Shares outstanding at June 30, 2024 56,266,661
Schedule of Company's outstanding warrants to purchase common stock	Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2023 28,584,580 $ 0.50 Warrants issued 1,000,000 0.30 Warrants expired (761,500 ) 0.37 Outstanding, June 30, 2024 28,823,080 $ 0.50 Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2022 35,586,980 $ 0.46 Warrants issued 5,873,750 0.25 Warrants exchanged (1,025,000 ) 0.25 Warrants expired (9,478,200 ) 0.30 Warrants exercised (973,750 ) 0.20 Outstanding, June 30, 2023 29,983,780 $ 0.49
Schedule of fair value warrants issued under Black-Scholes Option Pricing model	Expected term (years) 4.0 Volatility 389.2 % Risk-free interest rate 4.4 % Dividend yield 0.0 % Expected term (years) 3.9 Volatility 290.6 % Risk-free interest rate 3.7 % Dividend yield 0.0 %

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2024
STOCK OPTIONS
Schedule of Stock options vested, unvested and granted	Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of December 31, 2023 2,338,636 $ 0.41 6.5 years $ - Options outstanding as of June 30, 2024 2,338,636 $ 0.41 6.1 years $ - Options exercisable as of June 30, 2024 1,980,114 $ 0.43 5.6 years $ - Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of December 31, 2022 1,500,000 $ 0.49 7.5 years $ - Options granted 1,025,000 $ 0.26 Options forfeited (186,364 ) $ 0.31 Options outstanding as of June 30, 2023 2,338,636 $ 0.41 7.1 years $ - Options exercisable as of June 30, 2023 1,755,114 $ 0.45 6.2 years $ -
Schedule of Stock option activity	Expected term (years) 10.0 Volatility 366.4 % Risk-free interest rate 3.8 % Dividend yield 0.00 Expected term (years) 2.0 Volatility 182.8 % Risk-free interest rate 4.0 % Dividend yield 0.0 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2024
Fair value of the warrants using the Black-Scholes option pricing model	Expected term (years) 3.0 Volatility 108.7 % Risk-free interest rate 4.3 % Dividend yield 0.0 %
Schedule of Operating lease right-of-use assets and lease liabilities	(in thousands) June 30, December 31 2024 2023 Operating lease right-of-use assets $ 185 $ 227 Operating lease liabilities $ 203 $ 246
Schedule of Maturities of operating lease liabilities	(in thousands) Operating Lease Payments 2024 (remaining) 58 2025 118 2026 50 Total future lease payments 226 Less: discount (23 ) Total lease liabilities $ 203
Schedule of Weighted-average remaining lease term and discount rate	(in thousands) June 30, 2024 December 31, 2023 Weighted average remaining lease term (years) 1.9 2.4 Weighted average discount rate 11.4 % 11.4 %
Tranche Three [Member]
Fair value of the warrants using the Black-Scholes option pricing model	Expected term (years) 2.0 Volatility 172.1 % Risk-free interest rate 3.6 % Dividend yield 0.0 %
Tranche Two [Member]
Fair value of the warrants using the Black-Scholes option pricing model	Expected term (years) 1.0 Volatility 144.4 % Risk-free interest rate 3.6 % Dividend yield 0.0 %
Tranche One [Member]
Fair value of the warrants using the Black-Scholes option pricing model	Expected term (years) 2.0 Volatility 173.0 % Risk-free interest rate 3.4 % Dividend yield 0.0 %

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2024
NOTES PAYABLE
Schedule of Short-term notes payable, including related parties	Short-term notes payable June 30, 2024 December 31, 2023 Short-term promissory note $ 100 $ - Current portion of long-term promissory note 24 - Premium Finance (insurance) - 59 Debt Discount (12 ) - Short-term notes payable $ 112 $ 59

CONVERTIBLE DEBT (Tables)

CONVERTIBLE DEBT (Tables)	6 Months Ended
	Jun. 30, 2024
CONVERTIBLE DEBT
Scheduled of unamortized debt issuance costs	Senior Secured Convertible Debenture June 30, 2024 December 31, 2023 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Unamortized debt issuance costs - (12 ) Debt Discount - (38 ) Senior Unsecured Convertible Debenture $ 1,130 $ 1,080
Scheduled of note payable discount, unamortized debt issuance costs and unamortized debt discount	June 30, 2024 December 31, 2023 Short-term convertible promissory note $ 100 $ - Unamortized debt issuance costs (4 ) - Debt Discount (12 ) - Beneficial conversion feature (5 ) - 1800 Diagonal Lending Convertible Note $ 79 $ -

RELATED PARTY DEBT (Tables)

RELATED PARTY DEBT (Tables)	6 Months Ended
	Jun. 30, 2024
RELATED PARTY DEBT
Schedule of Long-term debt, related parties	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2023 57 Balance outstanding at December 31, 2023 $ 179 Interest accrued through June 30, 2024 5 Balance outstanding at June 30, 2024 $ 184 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2023 93 Payments on outstanding debt (25 ) Balance outstanding at December 31, 2023 $ 287 Interest accrued through June 30, 2024 7 Balance outstanding at June 30, 2024 $ 294
Schedule of Long-term debt, related parties debt obligations	Year Amount (in thousands) 2024 (remaining) 21 2025 519 2026 3 Total $ 543

INCOME (LOSS) PER SHARE OF CO_2

INCOME (LOSS) PER SHARE OF COMMON STOCK (Tables)	6 Months Ended
	Jun. 30, 2024
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Schedule of Earnings per share	June 30, 2024 2023 Net loss (1,199 ) (2,573 ) Basic weighted average number of shares outstanding 55,368 50,138 Net loss per share (basic) (0.02 ) (0.05 ) Diluted weighted average number of shares outstanding 55,368 50,138 Net loss per share (diluted) (0.02 ) (0.05 )

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2024
FAIR VALUE MEASUREMENTS
Schedule of fair value for liabilities measured on a recurring basis	Fair Value at June 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Diagonal Lending $100,050 promissory note - - 13 13 Total short-term liabilities at fair value $ - $ - $ 13 $ 13
Schedule of change in fair value instruments	Six Months Ended June 30, 2024 2023 Balance, beginning of period $ - $ (5 ) Inception of derivative liability 5 Change in fair value during the period 7 5 Balance, end of period $ 12 $ -

ORGANIZATION BACKGROUND AND B_2

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION
Accumulated deficit	$ (152.3)
Total stockholders' deficits	(4.7)
Working capital	(4.7)
Net loss including preferred dividend	(1.2)
Proceeds from warrant exercises	$ 0.2	$ 0.4

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,360	$ 1,360
Work in process	46	46
Finished goods	44	44
Inventory reserve	(818)	(818)
Total	$ 632	$ 632

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 1,614	$ 1,614
Less accumulated depreciation	(1,586)	(1,582)
Property, equipment and leasehold improvements, net	28	32
Equipment [Member]
Property and equipment, gross	951	951
Furniture and Fixtures [Member]
Property and equipment, gross	17	17
Software [Member]
Property and equipment, gross	634	634
Leasehold Improvement [Member]
Property and equipment, gross	$ 12	$ 12

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 356	$ 401
Professional fees	95	216
Interest	143	188
Vacation	29	27
Preferred dividends	210	228
Other accrued expenses	7	8
Total	$ 840	$ 1,068

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Accounts receivable	$ 2,047		$ 7,442
Accounts receivable, net of allowance	450		1,500
Deferred revenue	747,780		424,225	$ 509,101
Remaining net operating loss	3,800,000
Net operating loss carry forward	$ 66,400,000
Percentage amount of tax benefit	50%
Excess of insured limitations	$ 156,112		$ 156,112
Consultants and Executives [Member]
Expense for warrants		$ 1,361,143
Director [Member]
Expense related to stock options	29,673	206,306
Expense for warrants	$ 30,932	$ 116,000

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details)	6 Months Ended
	Jun. 30, 2024 shares
Issuances of common stock	2,161,560
Share outstanding, beginning	54,105,101
Common shares issued during the year ended	2,161,560
Share outstanding, ending	56,266,661
Issuances of Common Stock for Payment of Series D Preferred Dividends [Member]
Issuances of common stock	125,505
Issuances of Common Stock for Payment of Series E Preferred Dividends [Member]
Issuances of common stock	52,332
Issuances of Common Stock for Payment of Series F Preferred Dividends [Member]
Issuances of common stock	444,621
Issuances of Common Stock for Payment of Series F-2 Preferred Dividends [Member]
Issuances of common stock	235,544
Issuances of Common Stock for Payment of Interest [Member]
Issuances of common stock	903,558
Issuance of Common Stock to Consultants [Member]
Issuances of common stock	400,000

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS' DEFICIT:
Warrants outstanding, beginning balance	28,584,580	35,586,980
Warrants issued	1,000,000	5,873,750
Warrants cancelled/expired	(761,500)	(9,478,200)
Warrants exchanged		$ (1,025,000)
Warrants exercised		(973,750)
Warrants outstanding, ending balance	28,823,080	29,983,780
Weighted Average Exercise Price Per Share, beginning balance	$ 0.50	$ 0.46
Weighted Average Exercise Price Per Share, Warrants issued	0.30	0.25
Weighted Average Exercise Price Per Share, Warrants cancelled/expired	0.37	0.25
Weighted Average Exercise Price Per Share, Warrants exchanged		0.30
Weighted Average Exercise Price Per Share, Warrants exercised		0.20
Weighted Average Exercise Price Per Share, ending balance	$ 0.50	$ 0.49

STOCKHOLDERS DEFICIT (Details 2

STOCKHOLDERS DEFICIT (Details 2)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
STOCKHOLDERS' DEFICIT:
Expected term	4 years	3 years 10 months 24 days
Volatility	389.20%	290.60%
Risk-free interest rate	4.40%	3.70%
Dividend yield	0%	0%

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)		6 Months Ended		12 Months Ended
	May 14, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2021
Stock-based compensation expense		$ 29,673	$ 206,306
Common stock, par value		$ 0.001		$ 0.001
Outstanding shares exchanged to Preferred stock		53,674,649	54,482,496
Chinese National Medical Products Administration [Member]
Issuance of common stock	4,000,000
Strike price of warrants	$ 0.40
Warrant vested shares	1,500,000
Exercisable term	10 years
Food And Drug Administration [Member]
Warrant vested shares	2,500,000
Warrant [Member] | Mark Faupel [Member]
Issuance of common stock	4,000,000
Stock-based compensation expense			$ 679,959
Strike price of warrants	$ 0.25
Warrants Exchanges - 2021 [Member]
Common stock warrants		973,750
Strike price of warrants		$ 0.25	$ 0.25
Unpaid accrued dividends			$ 65,296
Exchange common stock warrants			1,025,000
Common stock warrants strike price per share			$ 0.20
Exercise of warrants, value			$ 194,750
Exercise of warrants, shares			973,750
Warrants Exchanges - 2021 [Member] | Richard Blumberg [Member]
Number of warrant issued		900,000	900,000
Series C Convertible Preferred Shares [Member]
Note payable to an unaffiliated third party		$ 100,000
Issuance of common stock		100,000
Common stock, shares authorized		500,000,000		500,000,000
Common stock shares issued		56,266,661		54,105,101
Common stock shares outstanding		56,266,661		54,105,101
Conversion price per share		$ 0.50
Common stock, par value		$ 0.001		$ 0.001
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		572,000
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares designated		9,000		9,000
Liquidation preference		$ 1,000		$ 1,000
Make-whole payment shares		200		200
Unpaid accrued dividends		$ 120,120		$ 120,120
Preferred stock shares issued		300		300
Preferred stock shares outstanding		300		300
Cumulative dividend rate		12%
Preferred stock shares authorized		9,000		9,000
Series C1 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.50
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		2,098,500
Preferred stock shares designated		20,250
Preferred stock shares issued		1,049		1,049
Preferred stock shares outstanding		1,049		1,049
Series C2 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.50
Preferred stock shares converts into common stock		2,000
Preferred stock shares converts into common stock		5,400,000
Preferred stock shares surrendered		3,262
Dividing the stated value		1,000
Preferred stock shares issued		3,262
Preferred stock shares outstanding		2,700		2,700
Series F-2 Convertible Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock shares converts into common stock		4,000
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares designated		3,500
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share		$ 1,000
Outstanding shares exchanged to Preferred stock		2,559
Preferred stock shares issued		500		500
Percentage of dividend		6%
Increased beneficial ownership percentage		9.99%
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200%
Preferred stock shares outstanding		520		520
Preferred stock shares received		678,000
Accrued dividends of preferred shares		$ 7,918		$ 23,579
Outstanding debt		$ 2,559,000
Issuance of common stock for conversion of Series F-2 Convertible Preferred Stock		235,544
Preferred stock shares outstanding		500		500
Preferred stock shares authorized		5,000		5,000
Series D Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock, par value		$ 0.001
Preferred stock shares designated		6,000
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share		$ 750
Preferred stock shares issued		763
Increased beneficial ownership percentage		9.99%
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200%
Preferred stock converted share		3,000
Shares issued common stock amount		$ 763,000
Common stock, issued public shares		1,526,000
Shares issued for payment of accured stock dividend		$ 125,505
Warrant exercise price per share		$ 0.25
Common stock warrants exercise price 1		$ 0.75
Preferred stock dividends accrued		$ 8,360		$ 8,360
Series E Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock, par value		$ 0.001
Preferred stock shares designated		5,000
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Liquidation preference		$ 883		883
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200%
Issuance of common stock for conversion of Series E Convertible Preferred Stock		52,332
Increased election holder		9.99%
Preferred stock stated value		$ 1,000
Accrued dividends		$ 57,592		$ 30,272
Cumulative dividends, per annum		8%
Series F Preferred Shares [Member]
Conversion price per share		$ 0.25
Preferred stock shares converts into common stock					4,000
Preferred stock shares designated		1,500
Conversion beneficial ownership limitation		4.99%
Maturity period		5 years
Stated value of preference share					$ 1,000
Preferred stock shares issued		1,006		1,006
Common Stock primary trading shares exceed		1,000
Exceeds percentage		200%
Shares issued common stock amount					$ 1,436,000
Issuance of common stock for conversion of Series F Convertible Preferred Stock		444,621
Increased election holder		9.99%
Preferred stock shares outstanding					1,436
Cumulative dividend rate					6%
Accrued dividends		$ 15,761		$ 46,108
Preferred Stock Shares [Member]
Preferred stock, par value		$ 0.001		$ 0.001
Preferred stock shares authorized		5,000,000		500,000,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
STOCK OPTIONS
Outstanding at beginning of year	2,338,636	1,500,000
Options granted		1,025,000
Options forfeited		(186,364)
Outstanding at ending of year	2,338,636	2,338,636
Number of shares exercisable	1,980,114	1,755,114
Options outstanding weighted average exercise price, beginning	$ 0.41	$ 0.49
Options granted weighted average exercise price	0.26	0.26
Options forfeited weighted average exercise price		0.31
Options outstanding weighted average exercise price, Ending	0.41	0.41
Weighted average exercise price per share exercisable	$ 0.43	$ 0.45
Weighted average remaining contractual life, Beginning	6 years 6 months	7 years 6 months
Weighted average remaining contractual life, Ending	6 years 1 month 6 days	7 years 1 month 6 days
Weighted average remaining contractual life exercisable	5 years 7 months 6 days	6 years 2 months 12 days
Agrregate intrensic value, Beginning	$ 0	$ 0
Agrregate intrensic value, Ending	0	0
Agrregate intrensic value exercisable	$ 0	$ 0

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1)		6 Months Ended
	Mar. 03, 2023	Jun. 30, 2023
Dr. Cartwright [Member]
Expected term (years)	2 years
Volatility	182.80%
Risk-free interest rate	4%
Dividend yield	0%
Black-Scholes Option [Member]
Expected term (years)		10 years
Volatility		366.40%
Risk-free interest rate		3.80%
Dividend yield		0%

STOCK OPTION (Details Narrative

STOCK OPTION (Details Narrative) - USD ($)				6 Months Ended
	Mar. 07, 2023	Mar. 03, 2023	Feb. 10, 2023	Jun. 30, 2024	Jun. 30, 2023
Unrecognized stock-based compensation expense				$ 94,578
Weighted average period				1 year 9 months
Aggregate number of common shares				2,500,000
Options granted weighted average exercise price				$ 0.26	$ 0.26
Vesting period, description	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023		One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023
Stock-based compensation expense				$ 29,673	$ 206,306
Director [Member]
Stock option expense				$ 29,673	206,306
Exercise price			$ 0.2629
Options granted			925,000
Maturity date			Feb. 09, 2033
Dr. Cartwright [Member]
Unvested stock options forfeited		186,364
Stock option expense					$ 59,216
Alan Gurjic [Member]
Exercise price	$ 0.27
Options granted	100,000
Maturity date	Mar. 06, 2033

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
Operating lease right-of-use assets	$ 185	$ 227
Operating lease liabilities	$ 203	$ 246

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
2024 (remaining)	$ 58
2025	118
2026	50
Total future lease payments	226
Less: discount	(23)
Total lease liabilities	$ 203	$ 246

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 2)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
COMMITMENTS AND CONTINGENCIES
Weighted average remaining lease term (years)	1 year 10 months 24 days	2 years 4 months 24 days
Weighted average discount rate	11.40%	11.40%

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES (Details 3)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Expected term (years)	4 years	3 years 10 months 24 days
Volatility	389.20%	290.60%
Risk-free interest rate	4.40%	3.70%
Dividend yield	0%	0%
Tranche Three [Member]
Expected term (years)	2 years
Volatility	3.60%
Risk-free interest rate	172.10%
Dividend yield	0%
Tranche Two [Member]
Expected term (years)	1 year
Volatility	3.60%
Risk-free interest rate	144.40%
Dividend yield	0%
Tranche One [Member]
Expected term (years)	2 years
Volatility	3.40%
Risk-free interest rate	173%
Dividend yield	0%
Richard Blumberg [Member]
Expected term (years)	3 years
Volatility	108.70%
Risk-free interest rate	4.30%
Dividend yield	0%

COMMITMENTS AND CONTINGENCIES_6

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

Mar. 10, 2021

Sep. 06, 2016

Jun. 05, 2016

Jul. 31, 2024

May 31, 2024

Apr. 26, 2024

Mar. 27, 2024

Feb. 17, 2024

Aug. 24, 2022

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Jun. 28, 2024

Jan. 22, 2020

Royalty percent

20%

Operating lease cost

$ 27,351

$ 54,702

Payment to advisory group per months

2,000

Description of standstill agreement

contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545

Warrants broken into four tranches

1,250,000

Strike price

$ 0.25

Warrants exercise prices

$ 0.25

Commitments Other [Member]

Consideration amount company received

$ 885,144

Tranche Second and Third [Member]

Stock price

$ 1.50

$ 1.50

Tranche Second [Member]

Recognized expense

$ 29,706

$ 29,706

$ 0

59,412

Unrecognized expense

0

Tranche Third [Member]

Recognized expense

$ 15,466

$ 15,466

30,932

30,932

Unrecognized expense

10,311

Shenghuo Medical, LLC [Member]

Payment receive descriptions

Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million

Royalty Agreement [Member]

Royalty consideration

$ 50,000

Agreement Smi Fund [Member]

Amendment payment from SMI

$ 531,100

Description related to SMI fund agreement

SMI, through SMI’s authorized distribution partner, initiated a wire payment of $330,000 in partial satisfaction of $531,100 owed to the Company

Description related to standstill agreement

The parties agreed that SMI will make a nonrefundable payment of $100,000 to the Company prior to March 31, 2024. In exchange, the Company will not initiate any legal proceedings, including but not limited to filing a lawsuit, obtaining a judgement, or enforcing any security interest, as related to the March shortfall in payments of $201,100, until April 30, 2024. Upon paying $100,000, SMI will have the option to extend the Standstill Agreement until June 15, 2024 by making a nonrefundable payment to the Company of $150,000

Additional Commitment payment

$ 500,000

$ 200,000

Additional payments

4,000,000

Consideration for inventory payment

$ 4,400,000

Alan Gurjic [Member]

Excercise price

$ 0.75

Weighted average price

$ 1.50

Advisory Group | Consulting Agreement [Member]

Warrants

831,250

831,250

5,000,000

Number of warrants issued

2,500,000

2,500,000

Strike price

$ 0.20

$ 0.20

Ironstone capital corp and Alan Gurjic [Member] | Consulting Agreement [Member]

Issued warrants

800,000

Excercise price

$ 0.50

Weighted average price

$ 1

Mr. Blumberg [Member]

Issued warrants

600,000

900,000

Shares issued

400,000

Mr. Blumberg [Member] | Consulting Agreement [Member]

Terms of amendment to agreement

3,600,000 3-year warrants with exercise prices ranging from $0.30 - $0.60, and (2) 1,600,000 common stock shares. On September 30, 2021, the Company and Mr. Blumberg entered into an amended agreement, pursuant to which issuance of the warrants and common shares became predicated on the Company obtaining financing or a series of financings resulting in minimum receipts of at least $1.0 million

royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20

Recognized expenses for Warrants issued

$ 0

590,840

Recognized expenses for common stock

$ 7,425

$ 111,833

Number of outstanding warrants for exchange

875,000

Subscription receivable

$ 350,000

Warrants exercise prices

$ 0.30

Mr. Blumberg [Member]

Number of warrants issued

1,750,000

1,750,000

Non-related parties [Member]

Number of warrants issued

750,000

750,000

Third Party [Member]

Issued warrants

600,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Short-term notes payable	$ 112	$ 59
Debt Discount	(12)	0
Premium Finance (Insurance) [Member]
Short-term notes payable	0	59
Short-Term Promissory Note [Member]
Short-term notes payable	100	0
Current Portion of Long-Term Promissory Note [Member]
Short-term notes payable	$ 24	$ 0

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrativeg) - USD ($)		1 Months Ended
	Jul. 04, 2023	Jun. 28, 2024	Apr. 15, 2024	Jun. 30, 2024	Dec. 31, 2023
Monthly payment	$ 12,041	$ 20,000	$ 2,000
Deferred compensation			81,768
Outstanding principal balance				$ 0	$ 59,422
Promissory note		$ 100,000	$ 87,162	83,162
Common stock purchase warrants		100,000
Short term note payable				112,000	59,000
Long term note payable				59,000	$ 0
Accrued interest		$ 10,000
Exercise price		$ 0.25
Discount on note payable		$ 11,998
Line of credit facility, maximum borrowing capacity	$ 129,073
Promissory note maturity date	May 04, 2024	Jan. 01, 2025	May 05, 2028
Accrued interest rate	7.90%		6%
Note payable [Member]
Short term note payable				24,000
Long term note payable				$ 59,162

CONVERTIBLE DEBT (Details)

CONVERTIBLE DEBT (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
1800 Diagonal Lending Convertible Note [Member]
Debt Discount	$ (12)	$ 0
Long-term convertible debt	79	0
Short-term convertible promissory note	100	0
Unamortized debt issuance costs	(4)	0
Beneficial conversion feature	(5)	0
10% Senior Unsecured Convertible Debenture [Member]
10% Senior Unsecured Convertible Debentures	1,130	1,130
Debt Issuance costs to be amortized	0	(12)
Debt Discount	0	(38)
Long-term convertible debt	$ 1,130	$ 1,080

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended
	Jun. 11, 2024	Sep. 02, 2022	May 17, 2021	Jun. 30, 2024	Jun. 28, 2024	Apr. 15, 2024	Dec. 31, 2023	Sep. 01, 2022	Dec. 17, 2019
Convertible promissory note									$ 2,400,000
Convertible debt conversion price description				The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date)
Trading price									$ 0.04
Variable conversion price									$ 0.15
Early prepayment penalty		$ 350,000
Default premiums		281,256
Interest payable		91,555
Reduced amount owed to Auctus after the Exchange		$ 710,911
Warrants exchanged by Auctus		8,775,000
Default penalty forgiven by Auctus		$ 225,444
Interest rate				24%
Notes payable				$ 83,162	$ 100,000	$ 87,162
Auctus [Member]
Accrued interest				115,646			$ 121,995
Share Issue		3,900,000
Prepayment penalty								$ 350,000
Total balance of the convertible debt outstanding				15,000			25,000	$ 1,228,183
Warrant One [Member]
Warrant exchange price		$ 0.50
Warrant to purchase								3,900,000
Warrant Two [Member]
Warrant exchange price		0.65
Warrant to purchase								3,900,000
Minimum [Member]
Warrant exchange price		0.15
Maximum [Member]
Warrant exchange price		$ 0.20
10% Senior Unsecured Convertible Debenture [Member]
Convertible promissory note			$ 1,000	1,130,000
Accrued interest				$ 24,860			$ 58,494
Convertible debentures right description			each debenture unit included 1,000 common stock warrants with an exercise price of $0.80 and an expiration date of May 17, 2023
Change of Control premium percentage			3%
Default interest rate				18%
Senior Secured Convertible rate			10%
Deemed price			$ 0.50
Debt maturity date			May 17, 2024	May 17, 2024
Proceeds from convertible debenture			$ 1,130,000
Conversion price			$ 0.50
1800 Diagonal Lending Note [Member]
Convertible promissory note				$ 100,000
Accrued interest	$ 14,007			$ 1,166
Convertible note principal balance	100,050
Discount on convertible note	13,050
Notes payable	$ 57,029
Debt maturity date	Apr. 15, 2025
Convertible note monthly payments	$ 14,257

RELATED PARTY DEBT (Details)

RELATED PARTY DEBT (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Bonus	$ 356	$ 401
Vacation	29	27
Dr. Cartwright [Member]
Salary	337
Bonus	675
Loans to Company	528
Interest on loans	81
Total outstanding prior to exchange	1,621
Amount forgiven in prior years	(1,302)
Total interest accrued	7	93
Balance outstanding, end of period	294	287
Amount exchanged for Series F-2 Preferred Stock	(100)
Payments on outstanding debt		(25)
Dr. Faupel [Member]
Salary	134
Bonus	20
Vacation	95
Interest on compensation	67
Loans to Company	196
Interest on loans	149
Total outstanding prior to exchange	661
Amount forgiven in prior years	(454)
Amount exchanged for Series F-2 Preferred Stock	(85)
Total interest accrued	5	57
Balance outstanding, end of period	$ 184	$ 179

RELATED PARTY DEBT (Details 1)

RELATED PARTY DEBT (Details 1) - Long-Term Debt - Related Parties [Member] - Mr. Fowler [Member] $ in Thousands	Jun. 30, 2024 USD ($)
2024 (remaining)	$ 21
2025	519
2026	3
Total	$ 543

RELATED PARTY DEBT (Details Nar

RELATED PARTY DEBT (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 22, 2021	Feb. 19, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jul. 14, 2018
Deferred compensation				$ 1,119,000	$ 60,000	$ 1,683,000
Dr. Cartwright [Member]
Promissory note interest rate		6%
Debt instrument converted amount		$ 100,000
Series F-2 Preferred Stock issued upon conversion of debt		100
Principal amount of promissory note		$ 267,085
Issuance of promissory note in exchange of related party debt								$ 319,000
Loans, interest, bonus, salary and vacation paid amount								$ 1,621,499
Interest rate per annum								6%
Dr. Faupel [Member]
Due to related party								$ 660,895
Promissory note interest rate		6%
Debt instrument converted amount		$ 85,000
Series F-2 Preferred Stock issued upon conversion of debt		85
Principal amount of promissory note		$ 153,178
Issuance of promissory note in exchange of related party debt								$ 207,111
Mr. Fowler [Member]
Deferred compensation			$ 16,401	$ 17,450	33,060	$ 35,171
Total outstanding prior to exchange			96,276		96,276
Long-term debt-related parties			$ 63,731		$ 63,731		$ 82,945
Due to related party	$ 546,214
Series F-2 Preferred Stock issued upon conversion of debt	50
Interest payable	$ 133,590
Due to related party, amount	$ 546,214
Promissory note default interest rate	18%
Promissory note monthly installment	$ 3,600
Preferred shares converted into common stock	200,000
Effective interest rate	6.18%
Deferred salary	$ 412,624
Unsecured note issued upon conversion of debt	$ 150,000

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Net loss	$ (758)	$ (1,604)	$ (1,199)	$ (2,573)
Basic weighted average number of shares outstanding			55,368	50,138
Net loss per share (basic)			$ (0.02)	$ (0.05)
Diluted weighted average number of shares outstanding			55,368	50,138
Net loss per share (diluted)			$ (0.02)	$ (0.05)

INCOME (LOSS) PER COMMON SHAR_2

INCOME (LOSS) PER COMMON SHARE (Details Narrative) - shares	Jun. 30, 2024	Jun. 30, 2023
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Convertible common shares	53,674,649	54,482,496

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Derivative liability	$ 13
Total short-term liabilities at fair value	13
Level 1 [Member]
Derivative liability	0
Total short-term liabilities at fair value	0
Level 2 [Member]
Derivative liability	0
Total short-term liabilities at fair value	0
Level 3 [Member]
Derivative liability	13
Total short-term liabilities at fair value	$ 13

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Ending Balance	$ 13
Derivative [Member]
Beginning Balance	0	$ (5)
Inception of derivative liability	5
Change in fair value during the year	7	5
Ending Balance	$ 12	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			1 Months Ended
	Aug. 03, 2024	Jul. 04, 2023	Jul. 31, 2024	Jul. 23, 2024	Jul. 22, 2024	Jun. 28, 2024	Apr. 15, 2024	Aug. 13, 2024	Jun. 30, 2024	Dec. 31, 2023	Dec. 17, 2019
Convertible promissory note											$ 2,400,000
Monthly Installments		$ 12,041				$ 20,000	$ 2,000
Common Stock, Issued									56,267,000	54,105,000
Interest payment									$ 143,000	$ 188,000
Subsequent Event [Member]
Warrants strike price			$ 0.25
Description of issuance of common stock			we issued 70,558 common shares for payment of Series D Preferred dividends and 213,151 common shares for payment of accrued interest expense
Common Stock, Issued			75,000
Subsequent Event [Member] | Finder's Fee Agreement [Member]
Annual interest rate	9%
Common stock, warrants issued	400,000
Subsequent Event [Member] | Unaffiliated Third Party [Member]
Convertible promissory note				$ 50,000				$ 25,000
Monthly Installments				$ 10,000
Warrants strike price				$ 0.25
Warrants expire date				Jul. 31, 2028
Common Stock, Issued				60,000
Accrued interest				$ 5,000
Interest payment				$ 5,000
Debt maturity date				Feb. 01, 2025
Subsequent Event [Member] | Diagonal Lending [Member]
Convertible promissory note					$ 62,100
Monthly Installments					8,849
Discount on convertible note					8,100
Accrued interest					8,694
Due to convertible notes					$ 35,397
Debt maturity date					May 30, 2025